Baxter voluntarily recalls Cefazolin in Dextrose injection after cardboard particles found

Baxter International announced a voluntary nationwide recall of Lot LD175708 of its Cefazolin in Dextrose Injection, a single-dose infusion bag.

The recall follows a report that cardboard particles were found in the solution, prompting the company to act to protect patients.

Baxter warned that infused foreign particles could cause pulmonary emboli, vascular occlusions, tissue death, organ damage, phlebitis, systemic immune activation, organ dysfunction, or hemolysis, although no adverse events have been reported so far.

The product, used intravenously to treat or prevent bacterial infections during surgery, is labeled 2 g/100 mL (20 mg/mL) and expires on February 14, 2027.